Qinghai Spring Medicinal Resources Technology Co Ltd (SHG:600381) — Market Cap & Net Worth
Market Cap & Net Worth: Qinghai Spring Medicinal Resources Technology Co Ltd (600381)
Qinghai Spring Medicinal Resources Technology Co Ltd (SHG:600381) has a market capitalization of $326.44 Million (CN¥2.23 Billion) as of September 16, 2026. Listed on the SHG stock exchange, this China-based company holds position #14463 globally and #4297 in its home market, demonstrating a -8.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Qinghai Spring Medicinal Resources Technology Co Ltd's stock price CN¥3.80 by its total outstanding shares 587060741 (587.06 Million). Also see how large is Qinghai Spring Medicinal Resources Techn's balance sheet for a full breakdown of the balance sheet.
Qinghai Spring Medicinal Resources Technology Co Ltd Market Cap History: 2015 to 2026
Qinghai Spring Medicinal Resources Technology Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.82 Billion to $326.44 Million (-13.98% CAGR). Also see Qinghai Spring Medicinal Resources Techn (600381) cash conversion ratio for how efficiently the company converts equity into cash flow.
Qinghai Spring Medicinal Resources Technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Qinghai Spring Medicinal Resources Technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Qinghai Spring Medicinal Resources Techn share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.11x
Qinghai Spring Medicinal Resources Technology Co Ltd's market cap is 1.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.32 Billion | $708.13 Million | $244.96 Million | 1.87x | 5.41x |
| 2017 | $911.46 Million | $471.12 Million | $310.54 Million | 1.93x | 2.94x |
| 2018 | $493.10 Million | $333.02 Million | $68.45 Million | 1.48x | 7.20x |
| 2019 | $463.03 Million | $233.75 Million | $5.81 Million | 1.98x | 79.73x |
| 2020 | $739.65 Million | $124.27 Million | -$319.54 Million | 5.95x | N/A |
| 2021 | $724.18 Million | $127.76 Million | -$248.61 Million | 5.67x | N/A |
| 2022 | $1.06 Billion | $160.18 Million | -$287.55 Million | 6.60x | N/A |
| 2023 | $664.05 Million | $213.88 Million | -$267.87 Million | 3.10x | N/A |
| 2024 | $313.55 Million | $270.26 Million | -$198.77 Million | 1.16x | N/A |
| 2025 | $380.56 Million | $343.42 Million | -$37.32 Million | 1.11x | N/A |
Competitor Companies of 600381 by Market Capitalization
Companies near Qinghai Spring Medicinal Resources Technology Co Ltd in the global market cap rankings as of September 16, 2026. Review Qinghai Spring Medicinal Resources Techn (600381) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Qinghai Spring Medicinal Resources Technology Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Qinghai Spring Medicinal Resources Technology Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Qinghai Spring Medicinal Resources Technology Co Ltd's market cap moved from $1.82 Billion to $ 326.44 Million, with a yearly change of -13.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥326.44 Million | -14.22% |
| 2025 | CN¥380.56 Million | +21.37% |
| 2024 | CN¥313.55 Million | -52.78% |
| 2023 | CN¥664.05 Million | -37.21% |
| 2022 | CN¥1.06 Billion | +46.03% |
| 2021 | CN¥724.18 Million | -2.09% |
| 2020 | CN¥739.65 Million | +59.74% |
| 2019 | CN¥463.03 Million | -6.10% |
| 2018 | CN¥493.10 Million | -45.90% |
| 2017 | CN¥911.46 Million | -31.19% |
| 2016 | CN¥1.32 Billion | -27.33% |
| 2015 | CN¥1.82 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Qinghai Spring Medicinal Resources Technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $326.44 Million USD |
| MoneyControl | $326.44 Million USD |
| MarketWatch | $326.44 Million USD |
| marketcap.company | $326.44 Million USD |
| Reuters | $326.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Qinghai Spring Medicinal Resources Technology Co Ltd
Qinghai Spring Medicinal Resources Technology Co., Ltd. manufactures and sells alcoholic beverages and health products in China. It operates through two segments, Wine and Beverage Fast-Moving Consumer Goods and Big Health. The Wine and Beverage Fast-Moving Consumer Goods segment focuses on the sales of alcoholic beverages, including the Tinghua series wines. The Big Health segment engages in the… Read more